A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Because of the effect in the treatment of NSCLC, the capecitabine and erlotinib may compose
to a new regimen for NSCLC. Based on the preclinical observation and the confirmed clinical
synergistic anti-tumor activity of combined capecitabine and erlotinib in gemzar refractory
advanced pancreatic cancer (APC), the investigators previously conducted a phase II study of
erlotinib in combination with capecitabine against NSCLC.